This biotech stock targeting genetic diseases could nearly double, predicts JPMorgan

This under-the-radar biotech is targeting genetic heart disorders with gene therapies could boost its stock price by 82%, according to JPMorgan.

Related Keywords

Tessa Romero , ,Lexeo Therapeutics ,Analyst Tessa Romero ,Lexeo Therapeutic ,Investment Strategy ,Stock Markets ,Lexeo Therapeutics Inc ,Business News ,